FB
Forte Biosciences, Inc.
FBRX · NASDAQ
$76.99 +0.03% (+$0.02)
1M +0.13%
Market Cap $1.58B
P/E Ratio -
Div. Yield -
ROE 94.82%
Bulios Fair Price
$46.34
39.8% downside
Current Price
$76.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, FBRX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 8.58x
P/FCF N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 16.25%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 42.74%
ROIC 49.43%
Debt
100 /100
Low Current ratio 10.01x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
19 /100
Unstable EPS volatility 47.09%
Profitable years 0
Beta 2.65x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about FBRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul A. Wagner
Employees
23
Headquarters
Dallas
Upcoming events
13 NOV
Earnings
Upcoming earnings report